Evidence map›Paper›PMID 29720629›Full record

ArticleClinical and translational gastroenterology2018

Aspirin: the miracle drug?

Prashanthi N Thota

Open access · goldAbstract readEditorial
In one paragraph

Article in Clinical and translational gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Prashanthi N ThotaDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA. thotap@ccf.org.
Cleveland Clinic · US

Funding

Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
NCI NIH HHS U54 CA163060
6 · The paper itself

Abstract

Aspirin use is associated with reduction of esophageal adenocarcinoma but it is not known if it does so by preventing the development of Barrett's esophagus or by reducing neoplastic progression in patients with Barrett's esophagus. There is sparse literature to support the former assumption especially in women. This study by Jovani et al. based on Nurses' Health Study reports 27% lower risk of Barrett's esophagus among women using aspirin. The protective effect seems to increase with higher frequency and longer duration of aspirin use. This study provides evidence for lower prevalence of Barrett's esophagus in female aspirin users.

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalAspirinBarrett EsophagusFemaleHumansMiddle AgedRisk AssessmentAnti-Inflammatory Agents, Non-SteroidalAspirin

Identifiers

PMID29720629
PMCPMC5932067
OpenAlexW2799558458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.